Hospital patients who took aspirin daily had a lower risk of admission, ventilation, and death in the intensive care unit SARS-CoV-2 Virus.
Hospitalization COVID-19 Patients who took low-dose aspirin daily to protect against cardiovascular disease had a significantly lower risk of complications and death than patients who did not take aspirin. This is what a new study conducted by researchers at the University of Maryland School of Medicine (UMSOM) revealed.
Aspirin users were less likely to be admitted to the intensive care unit (ICU) or on a mechanical ventilator, and were more likely to survive the infection than hospitalized patients who did not take aspirin. The study published on October 21, 2020, in the journal Anesthesia and analgesiaoffers “cautious optimism” for an inexpensive, accessible drug with a known safety profile that could help prevent serious complications.
“This is a critical finding that needs to be confirmed by a randomized clinical trial,” said lead investigator Jonathan Chow, MD, assistant professor of anesthesiology at UMSOM. “If our finding is confirmed, aspirin would be the first widely available over-the-counter drug to lower mortality in COVID-19 patients.”
To conduct the study, Dr. Chow and colleagues reviewed the medical records of 412 COVID-19 patients, an average of 55 years old, who were hospitalized in the past few months due to complications from their infection. You were treated at the University of Maryland Medical Center in Baltimore and three other hospitals on the east coast. About a quarter of patients took low-dose aspirin (usually 81 milligrams) daily before they were ingested or immediately after ingestion to treat their cardiovascular disease.
The researchers found that aspirin use resulted in a 44 percent reduction in the risk of being plugged into a mechanical ventilator, a 43 percent reduction in the risk of intensive care admission and, most importantly, a reduction in the risk of death in the hospital 47 percent was connected compared to those who did not take aspirin. The patients in the aspirin group did not show a significant increase in adverse events such as major bleeding in the hospital.
The researchers controlled various factors that may have played a role in a patient’s prognosis, including age, gender, body mass index, race, high blood pressure, and diabetes. They were also responsible for heart disease, kidney disease, liver disease, and the use of beta blockers to control blood pressure.
COVID-19 infections increase the risk of dangerous blood clots that can form in the heart, lungs, blood vessels, and other organs. Blood clot complications can rarely cause heart attacks, strokes, and multiple organ failure, as well as death.
Doctors often recommend a low-dose daily aspirin for patients who have previously had a heart attack or stroke caused by a blood clot to prevent future clots. However, daily use may increase the risk of severe bleeding or ulcer disease.
“We believe the blood-thinning effects of aspirin will benefit COVID-19 patients by preventing micro-clots from forming,” said study co-author Dr. Michael A. Mazzeffi, Associate Professor of Anaesthesiology at UMSOM. “Patients diagnosed with COVID-19 may want to consider taking a daily aspirin while checking with their doctor first.” People at increased risk of bleeding, for example, from chronic kidney disease or because they regularly take certain medications like steroids or blood thinners, may not be able to take aspirin safely, he added.
This study also included researchers from the Wake Forest School of Medicine, George Washington University Medical School, Northeast Georgia Health System, and Walter Reed National Military Medical Center.
“This study adds to the tremendous work our researchers at the School of Medicine are doing to find new therapies for COVID-19 and save patient lives,” said Dr. E. Albert Reece, MBA, Executive Vice President of Medicine Affairs, UM Baltimore and John Z. and Akiko K. Bowers Distinguished Professor and Dean of the University of Maryland School of Medicine. “While confirmatory studies are needed to prove that aspirin use leads to better results with COVID-19, what is known so far suggests that patients may want to discuss with their doctor whether it is safe for them to take aspirin to avoid potentially serious complications. ”
Reference: “Aspirin Use Has Been Associated with Decreased Mechanical Ventilation, Intensive Care Admission, and Hospital Mortality in Hospitalized Patients With COVID-19” by Chow, Jonathan H. MD; Khanna, Ashish K. MD; Kethireddy, Shravan MD; Yamane, David MD; Levine, Andrea MD; Jackson, Amanda M., MD, MAJ, MC, USA; McCurdy, Michael T. MD; Tabatabai, Ali MD; Kumar, Gagan MD; Park, Paul MD; Benjenk, Ivy RN, MPH .; Menaker, Jay MD; Ahmed, Nayab MD; Glidewell, Evan MD; Presutto, Elizabeth MD; Cain, Shannon MD; Haridasa, Naeha BS; Field, Wesley MD; Fowler, Jacob GBS; Trinh, Duy MD; Johnson, Kathleen NBS; Kaur, Aman DO; Lee, Amanda BS; Sebastian, Kyle MD; Ulrich, Allison MD; Peña, Salvador MD, PhD; Carpenter, Ross MD; Sudhakar, Shruti MD; Uppal, Pushpinder MD; Fedeles, Benjamin T., MD, Capt., USAF, MC; Sachs, Aaron MD; Dahbour, Layth MD; Teeter, William MD; Tanaka, Kenichi MD; Galvagno, Samuel M. DO, PhD; Sir, Daniel L. MD; Scalea, Thomas M. MD and Mazzeffi, Michael A. MD, MPH, October 21, 2020, Anesthesia & analgesia.
DOI: 10.1213 / ANE.0000000000005292